VLDLR and metabolic syndrome: A variety of genes thatplay pivotal roles in lipid metabolism, such as low-density lipoprotein receptor(LDLR), PCSK9, angiopoietin-like protein 3(ANGPTL3), apolipoprotein C3 (APOC3), and lipoprotein(a) (LPA),have been strategically targeted for the treatment of dyslipidemia,showcasing the versatility and promise of gene editing in this field.